19 May 2013
Keywords: Canada, Intellectual property monopolies, Patents, CETA, European Union, CGPA, Rx&D
Article | 27 June 2012
New data on R&D spending in Canada by brand-name drug companies provides further proof that there is no ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 June 2012
26 June 2012
17 May 2013
© 2013 thepharmaletter.com